D.H.E. 45
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Apr 1946
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
D.H.E. 45 is a legacy injectable medication approved in 1946 by Bausch + Lomb as a New Drug Application. The specific indication and mechanism of action are not documented in available data, limiting clinical context.
LOE Approaching
Product is in advanced stages of patent expiration with minimal linked job openings, indicating a contracting commercial footprint.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on D.H.E. 45 offers minimal career acceleration; the product is in late-lifecycle stage with zero linked job openings and no designated growth initiatives. Career value is limited to execution and compliance roles in a legacy portfolio.
Product ManagerField Sales Representative
Worked on D.H.E. 45 at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.